PKS Advisory Services LLC Buys Shares of 2,834 Johnson & Johnson (NYSE:JNJ)

PKS Advisory Services LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 2,834 shares of the company's stock, valued at approximately $436,000.

Several other institutional investors also recently bought and sold shares of JNJ. Raymond James Financial Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter worth about $1,339,878,000. Janus Henderson Group PLC increased its holdings in Johnson & Johnson by 228.1% during the 3rd quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company's stock worth $549,223,000 after purchasing an additional 2,356,359 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Johnson & Johnson by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock worth $33,666,460,000 after buying an additional 1,772,706 shares during the period. Franklin Resources Inc. raised its holdings in shares of Johnson & Johnson by 11.4% in the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock valued at $2,721,355,000 after acquiring an additional 1,729,281 shares in the last quarter. Finally, Amundi grew its holdings in Johnson & Johnson by 16.2% during the 4th quarter. Amundi now owns 11,930,183 shares of the company's stock worth $1,698,984,000 after acquiring an additional 1,660,458 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent research reports. Raymond James dropped their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Bank of America increased their price target on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a "neutral" rating in a research report on Wednesday, March 5th. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Leerink Partners lowered their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Finally, Stifel Nicolaus decreased their price objective on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $171.33.

Remove Ads

Johnson & Johnson Price Performance

NYSE:JNJ traded up $1.05 during trading hours on Friday, reaching $164.18. 2,877,042 shares of the company were exchanged, compared to its average volume of 9,052,445. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm has a market cap of $395.65 billion, a PE ratio of 24.68, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock's 50-day moving average is $158.35 and its 200-day moving average is $156.23.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the company posted $2.29 EPS. Johnson & Johnson's quarterly revenue was up 5.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.02%. Johnson & Johnson's dividend payout ratio is presently 74.59%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.